학술논문
Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study.
Document Type
article
Author
Marit J van Gils; Ayesha Lavell; Karlijn van der Straten; Brent Appelman; Ilja Bontjer; Meliawati Poniman; Judith A Burger; Melissa Oomen; Joey H Bouhuijs; Lonneke A van Vught; Marleen A Slim; Michiel Schinkel; Elke Wynberg; Hugo D G van Willigen; Marloes Grobben; Khadija Tejjani; Jacqueline van Rijswijk; Jonne L Snitselaar; Tom G Caniels; Amsterdam UMC COVID-19 S3/HCW study group; Alexander P J Vlaar; Maria Prins; Menno D de Jong; Godelieve J de Bree; Jonne J Sikkens; Marije K Bomers; Rogier W Sanders
Source
PLoS Medicine, Vol 19, Iss 5, p e1003991 (2022)
Subject
Language
English
ISSN
1549-1277
1549-1676
1549-1676
Abstract
BackgroundEmerging and future SARS-CoV-2 variants may jeopardize the effectiveness of vaccination campaigns. Therefore, it is important to know how the different vaccines perform against diverse SARS-CoV-2 variants.Methods and findingsIn a prospective cohort of 165 SARS-CoV-2 naive health care workers in the Netherlands, vaccinated with either one of four vaccines (BNT162b2, mRNA-1273, AZD1222 or Ad26.COV2.S), we performed a head-to-head comparison of the ability of sera to recognize and neutralize SARS-CoV-2 variants of concern (VOCs; Alpha, Beta, Gamma, Delta and Omicron). Repeated serum sampling was performed 5 times during a year (from January 2021 till January 2022), including before and after booster vaccination with BNT162b2. Four weeks after completing the initial vaccination series, SARS-CoV-2 wild-type neutralizing antibody titers were highest in recipients of mRNA-1273, followed by recipients of BNT162b2 (geometric mean titers (GMT) of 358 [95% CI 231-556] and 214 [95% CI 153-299], respectively; pConclusionsOverall, this study shows that the mRNA vaccines appear superior to adenovirus vector-based vaccines in inducing neutralizing antibodies against VOCs four weeks after initial vaccination and after booster vaccination, which implies the use of mRNA vaccines for both initial and booster vaccination.